11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Women’s Beliefs on Early Adherence to Adjuvant Endocrine Therapy for Breast Cancer: A Theory-Based Qualitative Study to Guide the Development of Community Pharmacist Interventions

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Adjuvant endocrine therapy (AET) taken for a minimum of five years reduces the recurrence and mortality risks among women with hormone-sensitive breast cancer. However, adherence to AET is suboptimal. To guide the development of theory-based interventions to enhance AET adherence, we conducted a study to explore beliefs regarding early adherence to AET. This qualitative study was guided by the Theory of Planned Behavior (TPB). We conducted focus groups and individual interviews among women prescribed AET in the last two years ( n = 43). The topic guide explored attitudinal (perceived advantages and disadvantages), normative (perception of approval or disapproval), and control beliefs (barriers and facilitating factors) towards adhering to AET. Thematic analysis was conducted. Most women had a positive attitude towards AET regardless of their medication-taking behavior. The principal perceived advantage was protection against a recurrence while the principal inconvenience was side effects. Almost everyone approved of the woman taking her medication. The women mentioned facilitating factors to encourage medication-taking behaviors and cope with side effects. For adherent women, having trouble establishing a routine was their main barrier to taking medication. For non-adherent women, it was side effects affecting their quality of life. These findings could inform the development of community pharmacy-based adherence interventions.

          Related collections

          Most cited references38

          • Record: found
          • Abstract: not found
          • Article: not found

          The Theory of Planned Behavior: A Review of Its Applications to Health-related Behaviors

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update.

            To update the ASCO clinical practice guideline on adjuvant endocrine therapy on the basis of emerging data on the optimal duration of treatment, particularly adjuvant tamoxifen. ASCO convened the Update Committee and conducted a systematic review of randomized clinical trials from January 2009 to June 2013 and analyzed three historical trials. Guideline recommendations were based on the Update Committee's review of the evidence. Outcomes of interest included survival, disease recurrence, and adverse events. This guideline update reflects emerging data on duration of tamoxifen treatment. There have been five studies of tamoxifen treatment beyond 5 years of therapy. The two largest studies with longest reported follow-up show a breast cancer survival advantage with 10-year durations of tamoxifen use. In addition to modest gains in survival, extended therapy with tamoxifen for 10 years compared with 5 years was associated with lower risks of breast cancer recurrence and contralateral breast cancer. Previous ASCO guidelines recommended treatment of women who have hormone receptor-positive breast cancer and are premenopausal with 5 years of tamoxifen, and those who are postmenopausal a minimum of 5 years of adjuvant therapy with an aromatase inhibitor or tamoxifen followed by an aromatase inhibitor (in sequence). If women are pre- or perimenopausal and have received 5 years of adjuvant tamoxifen, they should be offered 10 years total duration of tamoxifen. If women are postmenopausal and have received 5 years of adjuvant tamoxifen, they should be offered the choice of continuing tamoxifen or switching to an aromatase inhibitor for 10 years total adjuvant endocrine therapy. © 2014 by American Society of Clinical Oncology.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Adherence to endocrine therapy in breast cancer adjuvant and prevention settings.

              Adherence to oral endocrine therapy in adjuvant breast cancer settings is a substantial clinical problem. To provide current perspective on adherence to oral endocrine therapies, a comprehensive literature review was conducted. In adjuvant trials, endocrine therapy adherence is relatively high with greater adherence for aromatase inhibitors compared with tamoxifen. In contrast, adherence to adjuvant therapy in clinical practice is relatively poor, with only about 50% of women successfully completing 5-year therapy. Importantly, good adherence (>80% use) has been associated with lower recurrence risk. Endocrine therapy adherence in primary breast cancer prevention trials parallels that seen in adjuvant trials. Factors associated with nonadherence include low recurrence risk perception, side effects, age extremes, medication cost, suboptimal patient-physician communication, and lack of social support. Few prospective studies have evaluated interventions designed to improve adherence. Interventions currently proposed reflect inferences from clinical trial procedures in which clinical contacts are commonly greater than in usual practice settings. In conclusion, for optimal breast cancer outcome, adherence to endocrine therapy must improve. Although general recommendations likely to improve adherence can be made based on clinical trial results and preliminary prospective trial findings, research specifically targeting this issue is needed to establish effective intervention strategies.
                Bookmark

                Author and article information

                Journal
                Pharmacy (Basel)
                Pharmacy (Basel)
                pharmacy
                Pharmacy: Journal of Pharmacy Education and Practice
                MDPI
                2226-4787
                09 June 2018
                June 2018
                : 6
                : 2
                : 53
                Affiliations
                [1 ]Population Health and Optimal Health Practices, CHU de Quebec–Université Laval Research Centre, Hôpital du Saint-Sacrement, 1050 chemin Ste-Foy, Quebec, QC G1S 4L8, Canada; humphrib@ 123456mcmaster.ca (B.H.); steph1collins@ 123456hotmail.com (S.C.); laurence.guillaumie@ 123456fsi.ulaval.ca (L.G.); jocelyne.moisan@ 123456pha.ulaval.ca (J.M.)
                [2 ]Faculty of Pharmacy, Université Laval, 1050 avenue de la Médecine, Quebec, QC G1V 0A6, Canada; Anne.Dionne@ 123456pha.ulaval.ca
                [3 ]Department of Health Research Methods, Evidence and Impact, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4K1, Canada
                [4 ]Faculty of Pharmacy, Université de Montréal, 2940 Chemin de Polytechnique, Montréal, QC H3T 1J4, Canada
                [5 ]Faculty of Nursing, Université Laval, Quebec, 1050 avenue de la Médecine, Quebec, QC G1V 0A6, Canada
                [6 ]Oncology Research Unit, CHU de Quebec–Université Laval Research Centre, Hôpital du Saint-Sacrement, 1050 chemin Ste-Foy, Quebec, QC G1S 4L8, Canada; Julie.Lemieux@ 123456crchudequebec.ulaval.ca (J.L.); louise.provencher.cha@ 123456ssss.gouv.qc.ca (L.P.)
                [7 ]Centre des maladies du sein Deschênes-Fabia, CHU de Quebec–Université Laval, Hôpital du Saint-Sacrement, 1050 chemin Ste-Foy, Quebec, QC, G1S 4L8, Canada
                Author notes
                [* ]Correspondence: sophie.lauzier@ 123456pha.ulaval.ca ; Tel.: +1-418-682-7547
                Author information
                https://orcid.org/0000-0002-7237-1818
                https://orcid.org/0000-0003-1138-8285
                Article
                pharmacy-06-00053
                10.3390/pharmacy6020053
                6024955
                29890738
                e39cad3b-cc80-4479-8c16-338784808542
                © 2018 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 09 April 2018
                : 05 June 2018
                Categories
                Article

                oncology,breast cancer,medication adherence,tamoxifen,aromatase inhibitors qualitative research

                Comments

                Comment on this article